At You Can Discover Stocks, Post Anonymously, and React to Posts. No Login Required. Account Optional.
 More Stock Data
Pulse Portal
   TNXP   EBAY   BVTK   AMAT  'Buys'  SIRI   USLV   BOTZ  'Sells'  TSLA   JCP   TSLA  New: Labu15
Three Latest Stock Picks          by SpeculatingStocks
 Happening Now After Hours Gainers → TTOO  •  AMRN  •  KLIC  •  ESPR  •  FRED  •  BRKR  •  IMGN
 Happening Now After Hours Decliners → MSCC  •  WDC  •  STX  •  BLUE  •  NEOS  •  HIMX  •  AGTC
 Happening Now After Hours Active → AABA  •  MAT  •  CSCO  •  MSFT  •  AMAT  •  QQQ  •  CMCSA

Friday, September 2, 2016 Stock Pick ► Jaguar Animal Health, Inc. (JAGX)

Stock Price: $1.43

Jaguar Animal Health, Inc. develops and commercializes first-in-class gastrointestinal products for companion and production animals. Canalevia is the company's prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs.

JAGX just announced yesterday, September 1st, that their Neonorm Calf drug trial for cows met its topline goals. This is a great sign considering that the company also expressed that they are in the negotiation process for a potential exclusive distribution relationship for Neonorm in the Chinese market.

The Neonorm Calf product is non-prescription and designed to help dairies and calf farms proactively retain fluid in calves—helping the animals avoid debilitating, dangerous levels of dehydration.

JAGX currently trades at market cap of 15.90 million with a 52-week high of $4.70. The company had revenue of $258k in 2015, but the potential Chinese market deal could be a major catalyst to adoption of their Neonorm product.

JAGX has $3.87 million in cash on the balance sheet as of 6/30/2016. JAGX is a highly speculative play, but it traded 5.92 million shares on Thursday and is starting to get eyes on it and with a potential catalyst ahead, this could be a strong short-term play.

Speculative Score: 10

1 Being the Least Speculative and Most Confident

10 Being the Most Speculative and Possibly the Most Risky

Untitled Document